HUTCHMED (HCM) Stock Price, News & Analysis

Company Overview

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines research and development capabilities in China with international development and commercial operations, serving patients and healthcare providers in China, the United States, Europe and other global markets.

HUTCHMED’s oncology portfolio includes fruquintinib, a targeted therapy for certain patients with metastatic colorectal cancer. The medicine is marketed in China as Elunate and in the United States as Fruzaqla, and is commercialized internationally through partnerships. The company also developed savolitinib, a targeted therapy for certain forms of MET-driven non-small cell lung cancer that is marketed in China as Orpathys through a collaboration with AstraZeneca.

In addition to its commercial products, HUTCHMED maintains a pipeline of investigational medicines addressing solid tumors, hematologic cancers and immunological diseases. The company was established in 2000 and has expanded from a China-focused drug discovery business into an international biopharmaceutical company with research, clinical development and commercial activities across multiple geographies.

Key Stats

• Today's Range: $13.69 to $14.18
• 50-Day Range: $11.91 to $14.74
• 52-Week Range: $9.77 to $16.33
• Volume: 101,695 shs
• Average Volume: 50,098 shs
• Market Capitalization: $2.43 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.87
• Consensus Rating: Moderate Buy

HUTCHMED Stock Analysis - MarketRank™

HUTCHMED scored higher than 23% of companies evaluated by MarketBeat, and ranked 760th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

HUTCHMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for HUTCHMED is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

HUTCHMED has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -4.35%

Earnings Growth

Earnings for HUTCHMED are expected to decrease by -4.35% in the coming year, from $0.23 to $0.22 per share.

Price to Book Value per Share Ratio

HUTCHMED has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of HUTCHMED has been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 4.73.

Change versus previous month

Short interest in HUTCHMED has recently decreased by 3.87%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HUTCHMED does not currently pay a dividend.

Dividend Growth

HUTCHMED does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.07

News Sentiment

HUTCHMED has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for HUTCHMED this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HUTCHMED insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.60% of the stock of HUTCHMED is held by insiders.

Percentage Held by Institutions

8.82% of the stock of HUTCHMED is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 11/04/2026
• Fireside chat: 11/05/2026
• Deutsche Bank Virtual Investor Conference: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:HCM
• CIK: 1648257
• Web: www.hutch-med.com
• Phone: 852-2121-3888
• Fax: 852-2128-1778
• Employees: 1,796
• Year Founded: 2000

Price Target and Rating

• Average Price Target for HUTCHMED: $14.87
• High Price Target: $17.00
• Low Price Target: $13.60
• Potential Upside/Downside: +6.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 5.64
• Quick Ratio: 5.50

Sales & Book Value

• Annual Sales: $548.51 million
• Price / Sales: 4.43
• Cash Flow: $2.83 per share
• Price / Cash Flow: 4.92
• Book Value: $7.17 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 174,470,000
• Free Float: 168,186,000
• Market Cap: $2.43 billion
• Optionable: Optionable
• Beta: 0.30